Comparison of the Immunity Status in-Between Children with ÃÂ²-Thalassaemia Major Receiving Different Treatment Modalities: A Single Egyptian District StudyMahmoud SS1, Mohamed GB1, Hakeem GLA1*, Higazi AM2, Nafady AAH3, Farag NM2, Mahrous DM1, Kamal NN4, Hassan Z1, Aziz EA1 and Shaban A1
- *Corresponding Author:
- Gehan Lotfy Abdel Hakeem
Department of Pediatrics, Faculty of Medicine
Minia University, Minia, Egypt
E-mail: [email protected]
Received date: November 29, 2016; Accepted date: January 08, 2017; Published date: January 16, 2017
Citation: Mahmoud SS, Mohamed GB, Hakeem GLA, Higazi AM, Nafady AAH, et al. (2017) Comparison of the Immunity Status in-Between Children with β-Thalassaemia Major Receiving Different Treatment Modalities: A Single Egyptian District Study. Immunome Res 13:127. doi:10.4172/1745-7580.1000127
Copyright: © 2017 Mahmoud SS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract Background: β-thalassaemia major is one of the chronic hemolytic anemias resulting from defect in β-globin chain. It requires frequent blood transfusion plus other treatment modalities. These treatment modalities may be associated with certain immunologic modulations. Objective: To assess the immunity status in children with β-thalassaemia major under different treatment regimens within El Minia, Egypt. Subjects and Methods: One hundred forty-four children were enrolled and classified into four groups. Thirty-six β-thalassaemia patients treated only with blood transfusion (group I). Thirty-six patients treated with transfusion and iron chelation (group II). Thirty-six patients treated with transfusion, iron chelation and subjected to splenectomy (group III). Group IV involved thirty-six apparently healthy age and sex matched children. CBC plus serum levels of ferritin, IgA, complement C3 and C4 were measured along with detection of CD3+, CD4+, CD8+, CD19+ and CD56+ lymphocyte percentages and absolute counts. Results: IgA levels were significantly higher in thalassaemia patients compared to controls (p<0.001) plus highly significant increase in IgA levels in splenectomized patients than non-splenectomized (p<0.001). Levels of C3 were significantly decreased in all patients compared with controls (p=0.001) with a highly significant decrease in C3 levels in splenectomized patients than non splenectomized ones (p<0.001) but no statistical difference between their C4 levels. Significant statistical differences were revealed regarding CD3+, CD4+ and CD8+ T lymphocyte percentages within thalassaemia groups when compared to each other’s and to controls. Splenectomized patients had higher significant levels regarding serum ferritin (p=0.02) along with CD3+ (p=0.05), CD4+ (p=0.05) and CD8+ (p=0.037) lymphocyte percentages compared to non-splenectomized. CD19+ lymphocyte percentages were significantly higher while CD56+ lymphocyte percentages were significantly lower in all patients compared with controls (p=0.02 and 0.05). Conclusion: Immune modulation occurs in thalassaemia patients with regional specific variations and is related to variations in treatment modalities.